A small molecule smac mimic potentiates TRAIL- and TNFα-mediated cell death

Science

Volumn 305, Issue 5689, 2004, Pages 1471-1474

  Li, Lin ^a   Thomas, Ranny Mathew ^a   Suzuki, Hidetaka ^a   De Brabander, Jef K ^a   Wang, Xiaodong ^a,b   Harran, Patrick G ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN CANCER CELLS; SMAC;

CELLS; CHROMOSOMES; DISEASES; FLAMMABILITY; TUMORS;

PROTEINS;

ANTINEOPLASTIC AGENT; CASPASE; INHIBITOR OF APOPTOSIS PROTEIN; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

MEDICINE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS; WESTERN BLOTTING;

ALKYNES; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BIOTINYLATION; CARRIER PROTEINS; CASPASES; CELL LINE, TUMOR; COMPUTER SIMULATION; DIMERIZATION; DIYNES; GLIOBLASTOMA; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE GLYCOPROTEINS; MITOCHONDRIAL PROTEINS; MOLECULAR MIMICRY; NF-KAPPA B; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEINS; SIGNAL TRANSDUCTION; TETRAZOLES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 4444243683     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1098231     Document Type: Article

References (30)

1. N. A. Thornberry, Y. Lazebnik, Science 281, 1312 (1998).
2. Q. L. Deveraux, J. C. Reed, Genes Dev. 13, 239 (1999).
3. X. Wang, Genes Dev. 15, 2922 (2001).
4. J. Chai et al., Nature 406, 855 (2000).
5. A. G. Uren, M. Pakusch, C. J. Hawkins, K. L. Puls, D. L. Vaux, Proc. Natl. Acad. Sci. U.S.A. 93, 4974 (1996).
6. M. Rothe, M. G. Pan, W. J. Henzel, T. M. Ayres, D. V. Goeddel, Cell 83, 1243 (1995).
7. I. Imoto et al., Cancer Res. 61, 6629 (2001).
8. T. Hasegawa et al., Blood 101, 1164 (2003).
9. M. Krajewska et al., Clin. Cancer Res. 9, 4914 (2003).
10. C. Du, M. Fang, Y. Li, L. Li, X. Wang, Cell 102, 33 (2000).
11. A. M. Verhagen et al., Cell 102, 43 (2000).
12. Single-letter abbreviations for the amino acid residues are as follows: A, Ala; E, Glu; F, Phe; I, Ile; K, Lys; P, Pro; Q, Gln; and V, Val.
13. G. Wu et al., Nature 408, 1008 (2000).
14. Z. Liu et al., Nature 408, 1004 (2000).
15. S. Fulda, W. Wick, M. Weller, K. M. Debatin, Nat. Med. 8, 808 (2002).
16. O. E. Pardo et al., Mol. Cell. Biol. 23, 7600 (2003).
17. L. Yang et al., Cancer Res. 63, 831 (2003).
18. C. R. Arnt, M. V. Chiorean, M. P. Heldebrant, G. J. Gores, S. H. Kaufmann, J. Biol. Chem. 277, 44236 (2002).
19. This nomenclature refers to the AVPF prototype where the N-terminal L-alanine is position 1 and L-phenylalanine is position 4. Ten surrogates for a proline-phenylalanine dipeptide and 18 variable amino acid residues at position two were combined for a total of 180 compounds.
20. I-catalyzed cycloadditions of 2 to alkyl azides.
21. M. Mammen, S.-K. Choi, G. M. Whitesides, Angew. Chem. Int. Ed. Engl. 37, 2754 (1998).
22. Y. Huang, R. L. Rich, D. G. Myszka, H. Wu, J. Biol. Chem. 278, 49517 (2003).
23. Under conditions identical to those used in Fig. 1F, neither Smac nor compound 3 block the interaction of XIAP with activated caspases 3. However, both relieve XIAP suppression of caspase 3 activity (fig. S5).
24. Y. Deng, X. Ren, L. Yang, Y. Lin, X. Wu, Cell 115, 61 (2003).
25. C. Y. Wang, M. W. Mayo, R. G. Korneluk, D. V. Goeddel, A. S. Baldwin Jr., Science 281, 1680 (1998).
26. Z. L. Chu et al., Proc. Natl. Acad. Sci. U.S.A. 94, 10057 (1997).
27. D. A. Fox, Arch. Intern. Med. 160, 437 (2000).
28. J. Lam et al., J. Clin. Invest. 106, 1481 (2000).
29. R Berscheid, F Vögtle, Synthesis 1992, 58 (1992).
30. We thank O. Guryev for invaluable technical assistance, J. Chen for helpful discussions, N. Williams for preliminary toxicological data, and M. S. Brown and S. L. McKnight for helpful suggestions. Funding provided by a program project grant from the National Cancer Institute (PO1 CA95471). J.K.D. and P.G.H. are fellows of the Alfred P. Sloan Foundation. P.G.H. acknowledges unrestricted research awards from Eli Lilly, Pfizer, and AstraZeneca. Molecular interaction data have been deposited in the Biomolecular Interaction Network Database with accession codes 150999 to 151001.